Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 9085 results

  1. Epilepsies in children, young people and adults (SeLECTS)

    In development Reference number: GID-NG10453 Expected publication date:  05 August 2026

    NICE guideline
    In development

  2. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  3. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  4. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  5. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    In development Reference number: GID-TA11956 Expected publication date:  28 January 2027

    Technology appraisal guidance
    In development

  6. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Secukinumab for treating relapsed polymyalgia rheumatica ID6599: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 22 July 2026.

    Technology appraisal guidance
    In consultation

  8. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  10. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death caused by ventricular arrhythmia

    In development Reference number: GID-HTG10882 Expected publication date:  08 April 2027

    HealthTech guidance
    In development

  14. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTG10875 Expected publication date:  10 March 2027

    HealthTech guidance
    In development

  15. Inavolisib with pertuzumab–trastuzumab for maintenance treatment of PIK3CA-mutated HER2-positive advanced breast cancer after induction chemotherapy

    Awaiting development Reference number: GID-TA12441 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development